Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type
Open Access
- 20 November 2024
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 100 (1) , 66-77
Abstract
We retrospectively evaluated the impacts of using granulocyte colony‐stimulating factor (G‐CSF) and its timing on posttransplant outcomes for 9766 adults with acute myeloid leukemia (AML) between 2013 and 2022 using a Japanese database. We separately evaluated three distinct cohorts based on graft type: 3248 received bone marrow transplantation (BMT), 3066 received peripheral blood stem cell transplantation (PBSCT), and 3452 received single‐unit cord blood transplantation (CBT). Multivariate analysis showed that G‐CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT. However, it was associated with a higher risk of grades II–IV acute graft‐versus‐host disease (GVHD) across all graft types. Moreover, an increased incidence of overall chronic GVHD was observed with G‐CSF administration in BMT and CBT patients, but not in PBSCT patients. G‐CSF administration significantly improved overall survival (OS) and leukemia‐free survival (LFS) only following CBT. Regarding the timing of G‐CSF, in comparison with late initiation of G‐CSF (Days 5–10), early initiation (Days 0–4) did not provide benefits for hematopoietic recovery regardless of graft type. In contrast, late initiation was significantly associated with a lower risk of grades II–IV acute GVHD and better OS and LFS in CBT patients. These data demonstrated that G‐CSF administration accelerated neutrophil recovery and increased the risk of grades II–IV acute GVHD across all graft types, but significantly improved survival outcomes but only following CBT. Therefore, routine use of G‐CSF should be considered for CBT in adult patients with AML.Keywords
Funding Information
- Japan Agency for Medical Research and Development (18ek0510023h0002)
This publication has 35 references indexed in Scilit:
- Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program RegistryTransplantation and Cellular Therapy, 2024
- Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid MalignancyTransplantation and Cellular Therapy, 2021
- The Effect of Granulocyte Colony-Stimulating Factor Use on Hospital Length of Stay after Allogeneic Hematopoietic Cell Transplantation: A Retrospective Multicenter Cohort StudyTransplantation and Cellular Therapy, 2020
- Filgrastim following HLA-Identical Allogeneic Bone Marrow Transplantation: Long-Term Outcomes of a Randomized TrialTransplantation and Cellular Therapy, 2018
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantationBone Marrow Transplantation, 2000
- A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantationBone Marrow Transplantation, 1999
- Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantationBone Marrow Transplantation, 1999
- Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trialBone Marrow Transplantation, 1999